Story perspectives
Anti-Abortion Advocates Challenge FDA's Mifepristone Review
10/2/2025
47 7
1 of 1
Story summary
- Anti-abortion supporters criticize the Trump administration's review of mifepristone for insufficient research.
- Kristan Hawkins, president of Students for Life of America, sent letters to federal agencies demanding accountability.
- She argues past safety studies on mifepristone are insufficient because distribution has surged.
- Texas judge allowed a lawsuit against the Food and Drug Administration (FDA) over mifepristone, transferring it to Missouri.
